PARP1 and lung adenocarcinoma: The novel findings encountered in this study were that the pharmacological PARP inhibitor rucaparib elicited a significant improvement in tumor size, probably through a reduction in the cell proliferation rates resulting from the increased levels of DNA damage and apoptosis seen in the lung adenocarcinoma tumors of the treated mice.